Incretin drugs have been shown to improve glycemic variability (GV), and we recently showed that a switch from a combination of a dipeptidyl peptidase (DPP)-4 inhibitor plus basal insulin to insulin degludec/liraglutide (IDegLira) improves GV, including the mean amplitude of glycemic excursions (MAGE), using continuous glucose monitoring in hospitalized patients with Type 2 diabetes. Here, INS is linked to type 2 diabetes mellitus.